Detke HC, et al. - Subjects of age 18 to 65 years with a chronic migraine were examined to analyze the potency and safety of galcanezumab (a humanized monoclonal antibody) in phase 3 study of LY2951742 with a 3-month double-blind, placebo-controlled treatment phase and a 9-month open-label extension. Monthly subcutaneous injections of placebo, galcanezumab 120 mg or galcanezumab 240 mg were given to participants with a primary endpoint of overall mean change in the number of a monthly migraine headache days (MHDs) during the 3-month double-blind treatment phase. A decline in the number of monthly MHDs was observed in both galcanezumab dose groups. A higher rate of treatment-emergent injection-site reaction, injection-site erythema, injection-site pruritus, and sinusitis in the galcanezumab 240-mg group was estimated. Conclusively, galcanezumab (both doses) was effective, safer than placebo in diminishing the number of monthly MHDs and well tolerated for the preventive therapy of a chronic migraine.